Taysha Gene Therapies Return on Investment 2020-2024 | TSHA

Current and historical return on investment (ROI) values for Taysha Gene Therapies (TSHA) over the last 10 years.
Taysha Gene Therapies ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2024-06-30 $-0.08B $0.15B -89.28%
2024-03-31 $-0.08B $0.09B -158.79%
2023-12-31 $-0.07B $0.12B -225.00%
2023-09-30 $-0.11B $-0.01B -861.54%
2023-06-30 $-0.12B $0.00B -432.14%
2023-03-31 $-0.13B $0.02B -289.50%
2022-12-31 $-0.16B $0.04B -266.67%
2022-09-30 $-0.16B $0.05B -185.88%
2022-06-30 $-0.18B $0.07B -160.35%
2022-03-31 $-0.19B $0.09B -197.43%
2021-12-31 $-0.17B $0.13B -231.23%
2021-09-30 $-0.14B $0.17B -338.10%
2021-06-30 $-0.11B inf%
2021-03-31 $-0.07B inf%
2020-12-31 $-0.04B inf%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.314B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00